Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.91 |
| ▸ | CA6 | P23280 | 5/20 | 0.91 |
| ▸ | CA7 | P43166 | 5/20 | 0.91 |
| ▸ | CA9 | Q16790 | 5/20 | 0.91 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.91 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.91 |
| ▸ | MEN1 | O00255 | 2/20 | 0.91 |
| ▸ | RECQL | P46063 | 2/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.91 |
| ▸ | CA2 | P00918 | 4/20 | 0.83 |
| ▸ | CA4 | P22748 | 4/20 | 0.83 |
| ▸ | CA5A | P35218 | 4/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | CA3 | P07451 | 3/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.83 |
| ▸ | CA1 | P00915 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | TP53 | P04637 | 1/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL5699199 | 1.00 | CA12 (0.91) | CA12CA6CA7CA9CA14 | |
| SCHEMBL15381 | 0.95 | — | — | |
| SCHEMBL5314937 | 0.95 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL15797 | 0.91 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Ammonia Solution, Strong SCHEMBL902204 | 0.91 | — | — | |
| SCHEMBL25342018 | 0.91 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL2538760 | 0.91 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL25340653 | 0.91 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL15439 | 0.91 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL25342922 | 0.91 | CA12 (1.00) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999025385-A1 | A METHOD OF INCREASING NUCLEIC ACID SYNTHESIS WITH ULTRASOUND | IMARX PHARMACEUTICAL CORP. (US) | 1999-05-27 | — | — | WO | claimed |
| US-12590322-B2 | Devices and methods for mitochondria replacement and for generating cellular therapeutics | NanoCav, LLC (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4713348-A1 | DOUBLY CONSTRAINED PEPTIDES AS ALLOSTERIC INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | University of Georgia Research Foundation, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12565520-B2 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| WO-2025085624-A1 | INHIBITORS OF RAB-RILPL INTERACTIONS AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025076338-A1 | NANOBUBBLES FOR ULTRASOUND MEDIATED NUCLEIC ACID DELIVERY | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4467153-A1 | CONSTRAINED PEPTIDE INHIBITORS OF LRRK2-FADD INTERACTIONS | University of Georgia Research Foundation, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024238623-A1 | DOUBLY CONSTRAINED PEPTIDES AS ALLOSTERIC INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| US-20230372434-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | COHBAR, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11453701-B2 | Tau aggregation peptide inhibitors | ADRX, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220242912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220226484-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11332497-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-108884137-B | Peptides and their use in treating diseases, disorders, or conditions associated with mutant p53 | 耶达研究及发展有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11230578-B2 | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53 | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-01-25 | — | — | US | disclosed |
| CN-105579464-A | Peptides capable of reactivating p53 mutants | YEDA RES & DEV | 2016-05-11 | — | — | CN | disclosed |
| CN-1082043-C | Novel cationic lipids and the use thereof | IMARX PHARMACEUTICAL CORP (US) | 2002-04-03 | — | — | CN | disclosed |
| CN-1177342-A | Novel cationic lipids and the use thereof | IMAR PHARMACEUTICAL CORP (US) | 1998-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372434-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | MMP1, MMP8, COL2A1 | CA12 923/4885CA6 1268/4885CA7 1514/4885 |
| US-12565520-B2 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | CA12 4878/4885CA6 4882/4885CA7 4884/4885 |
| US-12590322-B2 | Devices and methods for mitochondria replacement and for generating cellular therapeutics | TFAM, TIMM9, MCU | CA12 3607/4885CA6 3446/4885CA7 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.